Evidence map›Paper›PMID 11319624›Full record

ArticleGene therapy2001

The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.

A S Majumdar, D E Hughes, S P Lichtsteiner, Z Wang, J S Lebkowski, A P Vasserot

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 116 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Frontiers in Suicide Gene Therapy of Cancer.Journal of genetic syndromes & gene therapy · 2012
    Article
  10. Review
  11. Article
  12. Article
  13. Targeting telomerase-expressing cancer cells.Journal of cellular and molecular medicine · 2011
    Review
  14. Article
  15. Article
  16. Use of the Rad51 promoter for targeted anti-cancer therapy.Proceedings of the National Academy of Sciences of the United States of America · 2008
    Article
  17. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2008
    Article
  18. Article
  19. Article
  20. Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2006
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

A S MajumdarGeron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA.
D E Hughes
S P Lichtsteiner
Z Wang
J S Lebkowski
A P Vasserot
Geron (United States) · USMenlo School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In human cells, telomerase activity is regulated by transcriptional control of the telomerase reverse transcriptase gene (hTERT) whose product is the catalytic subunit of the enzyme. The hTERT promoter is active in virtually all types of tumors and immortal cells, but is silent in most adult somatic tissues. In this study, we placed the herpes simplex virus thymidine kinase gene under the control of the hTERT promoter with the aim of restricting its expression to tumor cells. In transfection experiments, the hTERT promoter driven thymidine kinase gene (hTERTp/TK) conferred ganciclovir sensitivity to all tumor and immortal cell lines tested, whereas normal somatic cells remained largely unaffected. Human hTERTp/TK-positive cancer cells implanted in nude mice developed into tumors that could be eradicated by ganciclovir treatment. The hTERTp/TK cassette was inserted into an adenovirus vector and its efficacy in reducing tumor growth was compared with that of an adenovirus carrying the thymidine kinase gene under the control of the cytomegalovirus immediate-early promoter (CMVp/TK). In a xenograft model using the human 143B osteosarcoma cell line, a single injection of either virus resulted in equivalent tumor regression and survival upon ganciclovir treatment. In animals injected intratumorally with the CMVp/TK adenovirus, expression of the thymidine kinase gene was detected in tumors, as well as in liver samples. Expression of the suicide gene in combination with ganciclovir resulted in severe liver histopathology and in an elevation of hepatic enzymes. In sharp contrast, when the hTERT promoter controlled the thymidine kinase gene, transgene expression was observed in tumors, but not in liver samples. Normal liver function in these animals was confirmed by serum levels of hepatic enzymes that were indistinguishable from those of control healthy mice. These results indicate that by restricting thymidine kinase expression to tumor cells, the hTERT promoter allows the tumoricidal effect of the suicidal gene to be exerted without detrimental consequences on healthy tissues and vital organs. The tight specificity of expression imparted by the hTERT promoter will assist the development of novel approaches to the treatment of a broad array of cancer types.

Indexed as

Promoter Regions, GeneticRNAAdenoviridaeAnimalsDNA-Binding ProteinsGanciclovirGene Expression Regulation, NeoplasticGenetic TherapyGenetic VectorsHumansLiver DiseasesMiceMice, Inbred BALB CMice, NudeNeoplasm TransplantationOsteosarcomaDNA-Binding ProteinsGanciclovirRNARNA, MessengerTelomerasetelomerase RNAThymidine Kinase

Identifiers

PMID11319624
OpenAlexW2320037565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.